Notice of NIDA Participation in RFA-OD-24-014, "Botanical Dietary Supplements Translational Research Teams (RM1 Clinical Trial Required)"
Notice Number:

Key Dates

Release Date:

April 3, 2024

Related Announcements

  • March 14, 2024 - Botanical Dietary Supplements Translational Research Teams (RM1 Clinical Trial Required).  See NOFO RFA-OD-24-014

Issued by

National Institute on Drug Abuse (NIDA)


This notice informs potential applicants that the National Institute on Drug Abuse (NIDA) will participate in RFA-OD-24-014 "Botanical Dietary Supplements Translational Research Teams (RM1 Clinical Trial Required)," effective immediately.  (in Bold Italic):

Part 1. Overview Information

Components of Participating Organizations

Office of Dietary Supplements (ODS)
National Center for Complementary and Integrative Health (NCCIH)

National Institute on Drug Abuse (NIDA)

Assistance Listing Number(s)

93.321, 93.213, 93.279

 Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Specific Areas of Research Interest for Participating Organizations: This Notice encourages investigators with expertise and insights into clinical and basic aspects of botanical products to consider applying for this new NOFO, which supports transdisciplinary and translational research on chemically complex botanical or natural products traditionally used as dietary components to inform future clinical trials of the efficacy of exceptional dietary supplements. Specifically, the NOFO focused on filling in critical details in the molecular mechanism (e.g., what chemistry within these chemically complex and inherently variable has which biological activities, including toxicities, drug interactions, and potential beneficial effects)

NIDA Areas of Interest: NIDA seeks to support research that investigates how botanical or natural products may be beneficial in the treatment or prevention of substance use disorders (SUDs). Specifically, NIDA is interested in investigating the safety and effectiveness of botanical or natural products in individuals with SUD or at risk for SUD.  For example, psychoactive non-FDA regulated herbal remedies that are used to increase resilience to pain and mood disorders or substitute for substance use, such as Kratom, are of interest. Moreover, research projects with strong evidence of harm reduction and/or those that explore the molecular mechanism of botanical products that may be used for SUD treatment or prevention, including their complex chemical components, biological activities, pharmacological effects, toxicities, and drug interactions, would be appropriate.

Scientific/Research Contact(s):.

Jia Bei Wang, MD, Ph.D. 
National Institute on Drug Abuse 
Phone: 240-974-4703 

Financial/Grants Management Contact(s)

Amy Connolly
National Institute On Drug Abuse (NIDA)
Phone: 301-827-4457

All other aspects of the NOFO remain the same.


Please direct all inquiries to:

Jia Bei Wang, MD, Ph.D. 
National Institute on Drug Abuse (NIDA)
Phone: 240-974-4703